Journal of Cardiac Failure最新文献

{"title":"How Much Alcohol Is too Much for the Heart?","authors":"Belén Peiró-Aventín, Fernando Domínguez","doi":"10.1016/j.cardfail.2024.10.005","DOIUrl":"10.1016/j.cardfail.2024.10.005","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natriuretic Peptides For Diagnosing Heart Stress: Taking Action Now.","authors":"Enrique Santas, Antoni Bayes-Genís, Julio Núñez","doi":"10.1016/j.cardfail.2024.10.004","DOIUrl":"10.1016/j.cardfail.2024.10.004","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Revascularization Preferences With Best-Worst Scaling Among Patients With Ischemic Heart Disease.","authors":"Amrita Mukhopadhyay, Victoria Vaughan Dickson, Aisha Langford, John A Spertus, Sripal Bangalore, Yan Zhang, Thaddeus Tarpey, Judith Hochman, Stuart D Katz","doi":"10.1016/j.cardfail.2024.10.006","DOIUrl":"10.1016/j.cardfail.2024.10.006","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiologic Pacing for the Prevention and Treatment of Heart Failure A State-of-the-Art Review.","authors":"Margaret Infeld, Jamie A Cyr, Damián Sánchez-Quintana, Christopher Madias, James E Udelson, Daniel L Lustgarten, Markus Meyer","doi":"10.1016/j.cardfail.2024.08.063","DOIUrl":"https://doi.org/10.1016/j.cardfail.2024.08.063","url":null,"abstract":"<p><p>Permanent pacing from the right ventricular apex can reduce quality of life and increase the risk of heart failure and death. This review summarizes the milestones in the evolution of pacemakers towards \"physiologic pacing\" with biventricular pacing systems and lead implantation into the cardiac conduction system to synchronize cardiac contraction and relaxation. Both approaches aim to reproduce normal cardiac activation and help prevent and treat heart failure. This review introduces the basic concepts and clinical evidence and discusses practical uses of physiological pacing.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America.","authors":"Michelle Weisfelner Bloom, Jacqueline B Vo, Jo E Rodgers, Alana M Ferrari, Anju Nohria, Anita Deswal, Richard K Cheng, Michelle M Kittleson, Jenica N Upshaw, Nicolas Palaskas, Anne Blaes, Sherry-Ann Brown, Bonnie Ky, Daniel Lenihan, Mathew S Maurer, Anecita Fadol, Kerry Skurka, Christine Cambareri, Cynthia Chauhan, Ana Barac","doi":"10.1016/j.cardfail.2024.08.045","DOIUrl":"10.1016/j.cardfail.2024.08.045","url":null,"abstract":"<p><p>Heart failure and cancer remain 2 of the leading causes of morbidity and mortality, and the 2 disease entities are linked in a complex manner. Patients with cancer are at increased risk of cardiovascular complications related to the cancer therapies. The presence of cardiomyopathy or heart failure in a patient with new cancer diagnosis portends a high risk for adverse oncology and cardiovascular outcomes. With the rapid growth of cancer therapies, many of which interfere with cardiovascular homeostasis, heart failure practitioners need to be familiar with prevention, risk stratification, diagnosis, and management strategies in cardio-oncology. This Heart Failure Society of America statement addresses the complexities of heart failure care among patients with active cancer diagnoses and cancer survivors. Risk stratification, monitoring and management of cardiotoxicity are presented across stages A through D heart failure, with focused discussion on heart failure with preserved ejection fraction and special populations, such as survivors of childhood and young-adulthood cancers. We provide an overview of the shared risk factors between cancer and heart failure, highlighting heart failure as a form of cardiotoxicity associated with many different cancer therapeutics. Finally, we discuss disparities in the care of patients with cancer and cardiac disease and present a framework for a multidisciplinary-team approach and critical collaboration among heart failure, oncology, palliative care, pharmacy, and nursing teams in the management of these complex patients.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician: a Supplement to the Scientific Statement from the Heart Failure Society of America.","authors":"Michelle Weisfelner Bloom, Jacqueline B Vo, Jo E Rodgers, Alana M Ferrari, Anju Nohria, Anita Deswal, Richard K Cheng, Michelle M Kittleson, Jenica N Upshaw, Nicolas Palaskas, Anne Blaes, Sherry-Ann Brown, Bonnie Ky, Daniel Lenihan, Mathew S Maurer, Anecita Fadol, Kerry Skurka, Christine Cambareri, Ana Barac","doi":"10.1016/j.cardfail.2024.08.046","DOIUrl":"10.1016/j.cardfail.2024.08.046","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can't Rain on Our Parade: Highlights from the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024.","authors":"Alexander G Hajduczok, Elena M Donald, Jennifer Maning, Quentin Youmans, Nosheen Reza","doi":"10.1016/j.cardfail.2024.10.001","DOIUrl":"10.1016/j.cardfail.2024.10.001","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COUNTERPOINT: Abandon or Reassess? Interpreting Treatment Effects in \"Negative\" Clinical Trials.","authors":"Jessica R Overbey, Shelley Zieroth, Kert Viele","doi":"10.1016/j.cardfail.2024.09.007","DOIUrl":"10.1016/j.cardfail.2024.09.007","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142377848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FINEARTS Restoration: Revisiting the Role of Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure with Mildly Reduced or Preserved Ejection Fraction Following FINEARTS-HF.","authors":"Ricky D Turgeon, Craig J Beavers","doi":"10.1016/j.cardfail.2024.09.011","DOIUrl":"10.1016/j.cardfail.2024.09.011","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142377849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry","authors":"JENNIFER RYMER MD, MBA, MHS ,&nbsp;CAYLA PICHAN MD ,&nbsp;COURTNEY PAGE MA ,&nbsp;BROOKE ALHANTI PhD ,&nbsp;DEEPAK L. BHATT MD, MPH, MBA ,&nbsp;AJAR KOCHAR MD, MHS ,&nbsp;DOMINICK J. ANGIOLILLO MD, PhD ,&nbsp;MIGUEL DIAZ MD ,&nbsp;NEIL J. WIMMER MD, MSc ,&nbsp;RON WAKSMAN MD ,&nbsp;LAWRENCE ANG MD ,&nbsp;RICHARD BACH MD ,&nbsp;RONALD JENKINS MD ,&nbsp;HIJRAH EL-SABAE PharmD ,&nbsp;LEO BROTHERS MPH ,&nbsp;E. MAGNUS OHMAN MBBCh ,&nbsp;W. SCHUYLER JONES MD ,&nbsp;JEFFREY B. WASHAM PharmD ,&nbsp;TRACY Y. WANG MD, MHS, MSc ,&nbsp;DENNIS NARCISSE MD ,&nbsp;MIR B. BASIR DO","doi":"10.1016/j.cardfail.2024.08.003","DOIUrl":"10.1016/j.cardfail.2024.08.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Little is known about the use of cangrelor in patients with myocardial infarction (MI) presenting with cardiogenic shock (CS).</div></div><div><h3>Methods</h3><div>CAMEO (Cangrelor in Acute MI: Effectiveness and Outcomes) is a multicenter observational registry evaluating platelet inhibition in patients with MI. We examined the duration of cangrelor infusion and the amount of time to transition from cangrelor to an oral P2Y₁₂ inhibitor in patients with CS. We also assessed major adverse cardiovascular events (MACEs) and bleeding risks, stratified by dosage duration, time to transition and oral P2Y₁₂ inhibitor potency.</div></div><div><h3>Results</h3><div>Among 2352 cangrelor-treated patients with MI, 249 patients were in CS. Among the patients with CS, 16 (6.4%) received the “bridge” infusion dose, 202 (81.1%) the PCI cangrelor infusion dose, and 30 (12.0%) had a combination of both infusion doses. Patients with CS had a median age of 66 years; 32% were women; 21% were Black patients; 35% had diabetes; 19% received thrombectomy; and 59% received mechanical circulatory support (MCS) (35% intra-aortic balloon pump, 27% Impella). The median duration of infusion was 3.9 (2–21.5 hours) in patients with CS and was 2 (1.6–3.1 hours) for all cangrelor-treated patients. The median duration of transition from cangrelor to oral P2Y₁₂ inhibitor administration was 0.1 (-0.5–21.0 hours) for patients with CS. In multivariable modeling, chronic lung disease and the use of MCS and was associated with longer cangrelor infusions (defined as &gt; 3.9 hours). Among cangrelor-treated patients with CS, 24.1% of these patients had a bleeding event, and 41.8% had a MACE event. After adjustment, a longer cangrelor infusion duration was associated with increased risk of bleeding (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>The median duration of cangrelor infusion was longer for patients presenting with CS. Use of MCS was associated with longer cangrelor infusion durations in patients with CS. Further work is needed to understand the pharmacodynamics of antiplatelet agents in patients with CS.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 10","pages":"Pages 1233-1240"},"PeriodicalIF":6.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}